[go: up one dir, main page]

WO2007017546A3 - Method of obtaining tryptamine derivatives - Google Patents

Method of obtaining tryptamine derivatives Download PDF

Info

Publication number
WO2007017546A3
WO2007017546A3 PCT/ES2006/000465 ES2006000465W WO2007017546A3 WO 2007017546 A3 WO2007017546 A3 WO 2007017546A3 ES 2006000465 W ES2006000465 W ES 2006000465W WO 2007017546 A3 WO2007017546 A3 WO 2007017546A3
Authority
WO
WIPO (PCT)
Prior art keywords
obtaining
tryptamine derivatives
tryptamine
derivatives
rizatriptan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ES2006/000465
Other languages
Spanish (es)
French (fr)
Other versions
WO2007017546A2 (en
Inventor
Garrido Jose Vicente Murillo
Juarez Jorge Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ragactives SL
Original Assignee
Ragactives SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ragactives SL filed Critical Ragactives SL
Publication of WO2007017546A2 publication Critical patent/WO2007017546A2/en
Publication of WO2007017546A3 publication Critical patent/WO2007017546A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

The invention relates to a method of obtaining tryptamine derivatives (I), wherein R is a radical of a heterocycle, comprising the decarboxylation of the corresponding derivative of 3-(2-aminoethyl)-1H-indole carboxylic acid and the subsequent methylation of the amino group. Compounds (I) include zolmitriptan and rizatriptan which can be used for the treatment of migraines.
PCT/ES2006/000465 2005-08-08 2006-08-07 Method of obtaining tryptamine derivatives Ceased WO2007017546A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200501995A ES2270717B1 (en) 2005-08-08 2005-08-08 PROCEDURE FOR OBTAINING TRIPTAMINE DERIVATIVES.
ESP200501995 2005-08-08

Publications (2)

Publication Number Publication Date
WO2007017546A2 WO2007017546A2 (en) 2007-02-15
WO2007017546A3 true WO2007017546A3 (en) 2007-04-19

Family

ID=37727676

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2006/000465 Ceased WO2007017546A2 (en) 2005-08-08 2006-08-07 Method of obtaining tryptamine derivatives

Country Status (2)

Country Link
ES (1) ES2270717B1 (en)
WO (1) WO2007017546A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497512A2 (en) * 1991-02-01 1992-08-05 Merck Sharp & Dohme Ltd. Imidazole, triazole and tetrazole derivatives
ES2116411T3 (en) * 1992-06-05 1998-07-16 Merck Sharp & Dohme THE SULPHATE SALT OF A SUBSTITUTED TRIAZOLE, PHARMACEUTICAL COMPOSITIONS OF THE SAME AND ITS USE IN THERAPY
ES2204302A1 (en) * 2002-08-07 2004-04-16 Laboratorios Vita, S.A. Process for preparing zolmitriptan compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497512A2 (en) * 1991-02-01 1992-08-05 Merck Sharp & Dohme Ltd. Imidazole, triazole and tetrazole derivatives
ES2116411T3 (en) * 1992-06-05 1998-07-16 Merck Sharp & Dohme THE SULPHATE SALT OF A SUBSTITUTED TRIAZOLE, PHARMACEUTICAL COMPOSITIONS OF THE SAME AND ITS USE IN THERAPY
ES2204302A1 (en) * 2002-08-07 2004-04-16 Laboratorios Vita, S.A. Process for preparing zolmitriptan compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOLONEY G.P. ET AL.: "A Novel Series of 2.5-Substituted Tryptamine Derivatives as Vascular 5HT1B/1D Receptor Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, 1997, pages 2347 - 2362, XP002423191 *
STREET L.J. ET AL.: "Synthesis and Serotonergic Activity of N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and Analogues: Potent Agonists for 5-HT1D Receptors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, 1995, pages 1799 - 1810, XP000608327 *

Also Published As

Publication number Publication date
ES2270717A1 (en) 2007-04-01
WO2007017546A2 (en) 2007-02-15
ES2270717B1 (en) 2008-03-01

Similar Documents

Publication Publication Date Title
WO2007030574A3 (en) 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
IL189375A0 (en) 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero)aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
WO2007071766A3 (en) Phenoxy acetic acids as ppar delta activators
WO2008076862A3 (en) 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
WO2009145456A3 (en) Heterocyclic derivatives
WO2003070725A3 (en) Process for preparing indolinone derivatives
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
ZA201001335B (en) 2,3-substituted indole derivatives for treating viral infections
EA200900375A1 (en) SOLID LEMONIC ACID AND WINE ACID SALTS OF DPP-IV INHIBITORS
GB2407318A8 (en) Substituted indol-3-yl acetic acid derivatives
WO2006060535A3 (en) Indole derivatives for use as ppar active compounds
EP1828143A4 (en) 1H-PHENANTHRO [9,10-D] IMIDAZOLES SUBSTITUTED INTO 2 BY PHENYL OR HETEROCYCLE AS INHIBITORS OF MPGES-1
WO2007146716A3 (en) Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
NO20092694L (en) CRTH2 antagonists
WO2005105785A3 (en) Indole derivatives for treatment of obesity
WO2010001257A3 (en) Novel solid state forms of laquinimod and its sodium salt
WO2006034093A3 (en) 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors
WO2006118955A3 (en) Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles
NO20082096L (en) Azaindole-2-karboksamidderivativer
SG166829A1 (en) Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2009024823A3 (en) Cyclopropyl amide derivatives
WO2008104847A3 (en) Processes for the preparation of pramipexole and salts thereof
IL184885A0 (en) 7-{4-[2-(2,6-dihydro-4-methylphenoxy)ethoxyl]phenyl}-3,9-diazabicyclo[3.3.31]non-6-ene-s-carboxylic acid cyclopropyl-(2,3-dimethylbenzyd amide as inhibitors of renin for the treatment of hypertension
NO20090136L (en) Process for the preparation of salts of N-hydroxy-3- [4 - [[[2- (2-methyl-1H-1n-dol-3-yl) ethyl] amino] methyl] phenyl] -2E-2-propenamide
PL2158197T3 (en) Method for the preparation of high purity almotriptan

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06807911

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06807911

Country of ref document: EP

Kind code of ref document: A2